Company
PathoNostics was founded in 2011 in response to the growing global challenge of invasive fungal infections. As the dedicated sister company of PathoFinder—established in 2004 with a broader infectious disease focus—PathoNostics channels deep scientific expertise specifically into fungal diagnostics and molecular diagnostics. Our diverse, international team of mycology specialists and PCR developers is passionate about advancing real-time PCR technology to improve diagnostic accuracy and patient outcomes worldwide.
Using cutting-edge, proprietary multiplex real-time PCR technology and melting curve analysis, our diagnostic solutions deliver rapid and reliable identification of fungal pathogens and antifungal resistance markers. With clinically validated assays targeting invasive fungal infections, we empower laboratories and clinicians across more than 70 countries to make timely, precise treatment decisions with confidence.
At PathoNostics, we embrace the philosophy that we are “Big enough to lead, small enough to care.” This means we combine the leadership and innovation of a global molecular diagnostics company with attentive, personal support and close collaboration with our customers. Our team builds strong, trusted relationships through multiple touch points across the organization to ensure excellent service and ongoing partnership.
Our commitment to quality and accuracy is unwavering. We operate under ISO 13485:2016 standards and carefully monitor product performance through external quality assessments and ongoing clinical studies. With a Net Promoter Score of 71%, our partners continually recognize our dedication, expertise, and responsive service in fungal test diagnostics.
PathoNostics proudly stands at the forefront of fungal infection diagnostics, delivering molecular diagnostic PCR kits that allow healthcare professionals to act swiftly and accurately for those most vulnerable.
To be a global leader in better molecular diagnostic solutions.
We improve patient outcomes by innovating advanced molecular diagnostics.
Trust Expertise Growth Creativity Happiness
PathoNostics has an ISO13485:2016 certified Quality Management System (QMS) for the design and development, manufacture and distribution of In-Vitro Diagnostics for infectious diseases. All PathoNostics products are clinically validated according the IVD directive and results are published in scientific journals. PathoNostics participates yearly in the External Quality Assessment (EQA) programs of the Quality Control for Molecular Diagnostics (www.qcmd.org) and other international and national panels with highs cores on the performance. Results of these EAQ programs are available on request. The ISO13485:2016 certificate is available for download:
